Skip to main content
Fig. 1 | Stem Cell Research & Therapy

Fig. 1

From: HLA-mismatched GPBSC infusion therapy in refractory Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis: an observational study from a single center

Fig. 1

EBV-DNA before, 2 weeks and 4 weeks after treatment between two groups. There was no difference in EBV-DNA levels before treatment (p = 0.304) between two groups. In the GPBSC group, EBV-DNA decreased significantly after 2 weeks (p = 0.001) and 4 weeks (p = 0.012) after treatment, and the effect of the decrease was significantly better than that of the chemotherapy alone group in 2 weeks but not 4 weeks (p2w = 0.011, p4w = 0.145)

Back to article page

Stem Cell Research & Therapy

ISSN: 1757-6512